HOUSTON and LOUISVILLE, Ky., Nov. 13, 2018 /PRNewswire/ --NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that expanding applications of its proprietary NeXosome® liquid biopsy platform were presented at recent scientific conferences.
At the 6th Annual Advances in Prenatal Molecular Diagnostics conference in Cambridge, MA, Dr. Tom McElrath of Brigham & Women's Hospital presented clinical trial data demonstrating the utility of NeXosome-derived protein biomarkers in risk stratification for preterm birth and preeclampsia as early as week 10-12 of gestation. Currently, there are no marketed first trimester blood tests for preterm birth risk or preeclampsia risk, and physicians agree that new and effective tools for early risk identification are needed in order to positively impact clinical outcomes for these conditions.
At the Central Association of Obstetricians and Gynecologists Annual Meeting in Minneapolis, MN, Dr. David Haas of Indiana University School of Medicine presented pilot data demonstrating the feasibility of utilizing NeXosome-based protein biomarkers to evaluate the response of pregnant patients to progestin therapy, which is used for the prevention of preterm birth. Dr. Haas also presented methodological data demonstrating the effectiveness of the NeXosome platform in enriching maternal plasma samples for placental-derived exosomes, underscoring important "liquid biopsy" capabilities of NX Prenatal's technology platform.
"NX Prenatal is setting the stage for its exosome-based platform to play a significant role in identifying and monitoring for key risks in pregnancy at a time point that is actionable and has the potential to improve outcomes and drive tremendous cost from the system," commented Gail Page, Executive Chair for NX Prenatal. "We are creating a menu of tests that will allow physicians to augment their clinical observations with biologically important molecular data for personalized care in pregnancy."
About NX Prenatal
NX Prenatal Inc. is a private, US-based molecular diagnostics company. The company's proprietary NeXosome® platform is being utilized to develop enabling, early warning systems for pregnancies that may result in spontaneous preterm birth, preeclampsia and other adverse outcomes. NX Prenatal has demonstrated the clinical utility of its biomarker panels for prenatal risk assessment as early as 10 weeks gestation. This technology exploits biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal cells and tissues. For more information, please visit the company's website at www.nxprenatal.com.